J & J ’ s Cerenovus launches Galaxy G3 mini embolic coil, touts Arise II Embotrap study data

Johnson & Johnson‘s (NYSE:JNJ) Cerenovus division this week announced the launch of its Galaxy G3 Mini embolic coil and released data from a study of its Embotrap device designed to remove clots from the brain following ischemic stroke. The Galaxy G3 Mini coils are designed to be approximately 25% softer than the Galaxy G3 xsft coils, with an ultra-low coil profile and a primary wind diameter of 0.009 inches, which Cerenovus said is the lowest profile available in its Spectra line. The newly launched coil is designed to have a random complex shape to make it comformable and enable the device to seek and fill open spaces in cerebral aneurysms for higher packing densities, which the company said has been shown to lower patient retreatment rates. “Now, Cerenovus brings a family of endovascular coils that offers physicians a total procedural solution that can be used from start to finish or from periphery to core. We will continue to work to advance the treatment of cerebral aneurysm and both hemorrhagic and ischemic stroke to help physicians give stroke patients a new lease on life,” J&J medical devices cardiovascular & specialty solutions group chair Shlomi Nachman said in a press release. Cerenovus also released data from the Arise II study of its Embotrap device, touting high success rates in restoring blood flow with high rates of functional independence in patients treated with the device. Data from the study was presented this week at the Amer...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blood Management Business/Financial News Catheters Clinical Trials Neurological Vascular cerenovus johnsonandjohnson Source Type: news